Open AccessBronchial Asthma in Children Amidst the Novel Coronavirus Infection
Author(s) -
Е. Г. Фурман,
Ekaterina A. Khuzina,
М. N. Repetskaya
Publication year - 2020
Publication title -
doktor.ru
Language(s) - English
Resource type - Journals
eISSN - 2713-2994
pISSN - 1727-2378
DOI - 10.31550/1727-2378-2020-19-10-42-47
Subject(s) - asthma , coronavirus , medicine , covid-19 , disease , pandemic , immunology , infection control , intensive care medicine , infectious disease (medical specialty)
Objective of the Review: to present current information on monitoring and therapy of bronchial asthma (BA) in children amidst the novel coronavirus infection COVID-19. Key Points. There is no evidence that controlled BA increases the risk of SARS-CoV-2 infection or leads to more severe COVID-19. Inhaled glucocorticosteroids (IGCS) to manage BA inhibit gene expression of major SARS-CoV-2 target receptors. Anti-inflammatory BA therapy, primarily IGCS, should not be discontinued until BA is controlled, thus mitigating the risk of unfavourable course of COVID-19. Nebuliser therapy at home remains the preferred treatment in pre-school children with BA. Conclusion. Amidst the novel coronavirus infection COVID-19, children with BA should receive individualised therapy depending on disease severity and rate of disease control. Keywords: bronchial asthma, children, novel coronavirus infection COVID-19.